Lasma 4 Tablet contains Montelukast 4 mg, a leukotriene receptor antagonist used primarily in the management of asthma and allergic rhinitis. Montelukast works by selectively blocking leukotriene D4 receptors in the airway, thereby reducing bronchoconstriction, inflammation, and mucus production associated with asthma and allergic responses. This medication is indicated for the prophylaxis and chronic treatment of asthma in pediatric patients aged 2 to 5 years, helping to prevent asthma attacks and improve overall respiratory function. Additionally, Lasma 4 Tablet is effective in alleviating symptoms of seasonal allergic rhinitis, such as nasal congestion, sneezing, and runny nose. It is administered orally, typically once daily in the evening, to optimize its anti-inflammatory effects during nighttime when symptoms often worsen. Montelukast is generally well-tolerated, with common adverse effects including headache, abdominal pain, and occasional behavioral changes. It is important to note that Lasma 4 Tablet is not intended for the relief of acute asthma attacks and should be used as part of a comprehensive asthma management plan under medical supervision. Patients should adhere to prescribed dosages and consult healthcare providers before initiating or discontinuing therapy to ensure optimal therapeutic outcomes.